OOIR: Observatory of International Research

Papers

(The H4-Index of Clinical and Experimental Dermatology is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Treatment options for leishmaniasis	73
Anti‐interleukin‐23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real‐world practice	60
COVID‐19 vaccine‐induced Stevens–Johnson syndrome	55
Skin manifestations of COVID‐19 in children: Part 1	53
Performance of ChatGPT on Specialty Certificate Examination in Dermatology multiple-choice questions	47
Line‐field optical coherence tomography: in vivo diagnosis of basal cell carcinoma subtypes compared with histopathology	44
Janus kinase inhibitors for atopic dermatitis: a promising treatment modality	43
COVID‐19 vaccination and patients with psoriasis under biologics: real‐life evidence on safety and effectiveness from Italian vaccinated healthcare workers	42
Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID‐19 vaccine	41
Novel targets and therapies for keloid	40
De novo generalized pustular psoriasis following Oxford‐AstraZeneca COVID‐19 vaccine	39
Induction and exacerbation of subacute cutaneous lupus erythematosus following mRNA‐based or adenoviral vector‐based SARS‐CoV‐2 vaccination	39
Line‐field confocal optical coherence tomography for actinic keratosis and squamous cell carcinoma: a descriptive study	39
Skin manifestations of COVID‐19 in children: Part 2	37
Asymmetrical cutaneous vasculitis following COVID‐19 vaccination with unusual eosinophil preponderance	36
Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns	36
The impact of COVID-19 infection on patients with psoriasis treated with biologics: an Italian experience	35
Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on ‘Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?’	35
Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics	33
Associations of particulate matter with atopic dermatitis and chronic inflammatory skin diseases in South Korea	33
A flare of pre‐existing erythema multiforme following BNT162b2 (Pfizer–BioNTech) COVID‐19 vaccine	31
Clinical characteristics and disease burden in prurigo nodularis	31
Vitiligo in a COVID‐19‐vaccinated patient with ulcerative colitis: coincidence?	29
ChatGPT-3.5 and ChatGPT-4 dermatological knowledge level based on the Specialty Certificate Examination in Dermatology	27
Different types of emollient cream exhibit diverse physiological effects on the skin barrier in adults with atopic dermatitis	27

Vitiligo: an update on systemic treatments